Add-on treatment of dutasteridey to tadalafil for patients with benign prostatic enlargement

Add-on treatment of dutasteridey to tadalafil for patients with benign prostatic enlargement - Add-on treatment of dutasteridey to tadalafil for patients with benign prostatic enlargement

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034701

Enrollment

Registered

2018-11-01

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

Add-on treatment of dutasteride

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patinets with 30ml over of prostate volume and IPSS>8 or QOL>3 by 3months of tadalafil treatment

Exclusion criteria

Exclusion criteria: Patients who don't accept the study

Design outcomes

Primary

Measure	Time frame
Improvement of IPSS	—

Countries

Japan

Contacts

Public ContactNaoki Wada

Asahikawa Medical University Department or Renal and Urologic Surgery

nwada@asahikawa-med.ac.jp0166-68-2533

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026